Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) major shareholder Michael Rapp bought 15,000 shares of Zynerba Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The stock was purchased at an average cost of $12.99 per share, for a total transaction of $194,850.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Michael Rapp also recently made the following trade(s):
- On Monday, October 23rd, Michael Rapp bought 25,745 shares of Zynerba Pharmaceuticals stock. The stock was purchased at an average cost of $9.94 per share, for a total transaction of $255,905.30.
- On Thursday, October 19th, Michael Rapp bought 44,255 shares of Zynerba Pharmaceuticals stock. The stock was purchased at an average cost of $9.59 per share, for a total transaction of $424,405.45.
Shares of Zynerba Pharmaceuticals Inc (ZYNE) opened at $12.70 on Friday. Zynerba Pharmaceuticals Inc has a 1 year low of $5.42 and a 1 year high of $25.95. The stock has a market cap of $172.13 and a PE ratio of -4.90.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.05). During the same quarter last year, the firm posted ($0.67) EPS. analysts forecast that Zynerba Pharmaceuticals Inc will post -2.49 EPS for the current fiscal year.
A number of research analysts recently commented on the company. Cantor Fitzgerald set a $17.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday. Oppenheimer reissued a “hold” rating on shares of Zynerba Pharmaceuticals in a research note on Wednesday. Zacks Investment Research raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 8th. Canaccord Genuity set a $18.00 price target on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, December 4th. Finally, Piper Jaffray Companies upped their price target on shares of Zynerba Pharmaceuticals from $16.00 to $20.00 in a research report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. Zynerba Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $15.00.
Several institutional investors have recently bought and sold shares of ZYNE. JPMorgan Chase & Co. boosted its holdings in shares of Zynerba Pharmaceuticals by 65,190.0% during the second quarter. JPMorgan Chase & Co. now owns 326,450 shares of the company’s stock worth $5,539,000 after purchasing an additional 325,950 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of Zynerba Pharmaceuticals by 230.7% during the third quarter. Perceptive Advisors LLC now owns 130,700 shares of the company’s stock worth $1,320,000 after purchasing an additional 230,700 shares during the period. Citigroup Inc. boosted its holdings in shares of Zynerba Pharmaceuticals by 13,501.1% during the second quarter. Citigroup Inc. now owns 221,698 shares of the company’s stock worth $3,762,000 after purchasing an additional 220,068 shares during the period. RTW Investments LP purchased a new stake in shares of Zynerba Pharmaceuticals during the third quarter worth about $1,672,000. Finally, State Street Corp purchased a new stake in shares of Zynerba Pharmaceuticals during the second quarter worth about $2,698,000. Institutional investors own 26.71% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Michael Rapp Buys 15,000 Shares of Zynerba Pharmaceuticals Inc (ZYNE) Stock” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://transcriptdaily.com/2018/01/05/michael-rapp-buys-15000-shares-of-zynerba-pharmaceuticals-inc-zyne-stock.html.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.